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Our restriction fragment length polymorphism (RFLP) studies have shown that the most prevalent (40%)
strains of Mycobacterium tuberculosis from South India contain a single copy of the IS6110 insertion sequence
and are of importance in studying virulence and immunity. Sonicate antigens from seven such strains were
used to study in vitro T-cell proliferation and gamma interferon (IFN-) and interleukin-12 (IL-12) secretion
as markers of protective immunity in 25 healthy subjects positive for purified protein derivative (PPD). The
standard PPD and heat-killed H37Rv antigens induced the maximum levels of T-cell proliferation and IFN-
secretion but low levels of IL-12. All sonicate antigens induced T-cell proliferation and IFN- secretion with
strong positive correlation. Our results suggest that sonicate antigens from the most prevalent and recent
strains of M. tuberculosis from clinical isolates have the potential to induce T-cell activation and may allow
newer and specific antigens to be further characterized for diagnosis and vaccine development.
Tuberculosis remains a major international health problem
which is likely to become even more critical in coming years
because of the high incidence of human immunodeficiency
virus disease in regions where infection with the intracellular
pathogen Mycobacterium tuberculosis is endemic. Although
BCG (live attenuated Mycobacterium bovis) vaccine used
against tuberculosis is available, its protective efficacy ranged
from 0 to 80% in different clinical trials (9, 16). Therefore,
more effective antituberculosis vaccines are required to combat
the tuberculosis epidemic. The criterion for developing such
vaccines is to select the mycobacterial antigens from the cur-
rent and most prevalent M. tuberculosis strains from clinical
isolates in the community, which may induce a greater immune
response than the standard laboratory strains do. In many
reports, extracellular antigens or the secretory proteins re-
leased by live M. tuberculosis in the culture medium have been
tested for their vaccine potential and demonstrated to induce
substantial levels of protection in animal models (2, 13, 18) and
also in in vitro studies (8, 21). However, the culture filtrate
proteins used in these studies were conditionally secreted and
showed varied protein profiles. In recent studies, whole-cell
lysate or sonicate antigens of M. tuberculosis inclusive of cyto-
solic proteins and membrane proteins have also been used for
diagnostic purposes (11, 19) and to induce protective immunity
(23).
Our restriction fragment length polymorphism studies have
shown that about 40% of M. tuberculosis strains from South
India contain a single copy of the IS6110 insertion sequence in
the genomic DNA and are widely spread in the community (6).
The insertion of this mobile genetic element occurs at different
sites in the genome and may influence the phenotype of the
strains, which is of importance in studying their virulence and
role in immunity (20). In this study, we prepared sonicate
antigens from the most prevalent strains of M. tuberculosis
obtained from the BCG trial area of Tiruvallur District, South
India, and characterized them epidemiologically by restriction
fragment length polymorphism studies using an IS6110 probe
(15). We assessed their ability to induce protective immunity in
healthy subjects by studying the lymphoproliferative response
and cytokine response to these antigens as markers of T-cell
activation and compared them with standard purified protein
derivative (PPD)- and M. tuberculosis H37Rv-induced re-
sponses.
In total 14 clinical strains with a single copy of IS6110 were
selected based on different insertion sites of this mobile genetic
element in the genome and designated S1 to S14. Out of 14,
seven sonicate antigens (S1, S2, S6, S7, S8, S10, and S12)
showed differential expression of proteins in a low-molecular-
mass region (12 to 30 kDa) by sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis (J. Madhumathi et al., personal
communication) and hence were selected for further studies of
T-cell activation markers. The sonicate antigens were prepared
by sonicating the bacilli in Soniprep 150. The supernatants
after centrifugation were filtered through a 0.45-m-pore-size
membrane and stored in aliquots at 70°C. The protein con-
tent was determined by Lowry’s method (Bangalore Genei).
The peripheral blood mononuclear cells (PBMC) were pre-
pared from 25 healthy, PPD-positive laboratory volunteers by
Ficoll-Hypaque (Amersham) density gradient centrifugation.
In total 0.1  106 cells/well were cultured in round-bottomed
96-well plates (Nunclon; Nunc, Roskilde, Denmark) in tripli-
cate with PPD (10 g/ml) (Ministry of Fisheries, Weybridge,
Surrey, United Kingdom), heat-killed H37Rv (10 g/ml; whole
bacilli killed at 80°C for 30 min), and sonicate antigens (10
g/ml). Proliferation was assessed by measuring [3H]thymidine
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incorporation (0.5 Ci/well) by liquid scintillation counting
(Wallac 1409 liquid scintillation counter).
For the cytokine assay, 0.5  106 cells/ml were cultured in
flat-bottomed 48-well plates (Costar, Cambridge, Mass.) with
the above antigens and incubated at 37°C in a 5% CO2 incu-
bator for 5 days. The culture supernatants were harvested and
stored immediately at 70°C until the enzyme-linked immu-
nosorbent assay was done. Gamma interferon (IFN-) and
interleukin-12 (IL-12) levels were estimated by using a sand-
wich enzyme-linked immunosorbent assay kit (R & D Systems)
according to the manufacturer’s instructions. Arithmetic
means and standard errors of the means were calculated. The
significance of differences was estimated by Student’s paired t
test.
Tuberculosis is endemic in South India, and the population
there is already sensitized to mycobacterial antigens and/or
most of it is infected with M. tuberculosis. These individuals
would have developed protective immunity to M. tuberculosis,
and studying their immune response to these newer sonicate
antigens would be more relevant to correlating effective pro-
tective immunity. Hence, we studied the in vitro response of
PPD-positive healthy laboratory volunteers to the above anti-
gens. Lymphoproliferation and IFN- secretion are the param-
eters of T-cell activation and establish the induction of immune
response (1, 10). PBMC are rich in T cells that actively prolif-
erate and secrete IFN- in vitro. Our results for T-cell prolif-
eration and IFN- levels are summarized in Fig. 1 and 2. As
expected, the standard antigens, PPD and H37Rv, showed the
maximum proliferative response and IFN- production (P 
0.01) compared to the control cells. In total 80 to 92% of the
FIG. 1. Lymphoproliferative responses of 25 healthy subjects to sonicate antigens from clinical isolates (S1, S2, S6, S7, S8, S10, and S12) of M.
tuberculosis and standard antigens, PPD and H37Rv. Results are individual counts per minute and means. Statistical significance: , P  0.001;
, P  0.01; , P  0.05. CON, control.
FIG. 2. IFN- levels in healthy laboratory volunteers induced by M. tuberculosis sonicate antigens from clinical isolates (S1, S2, S6, S7, S8, S10,
and S12) and standard antigens, PPD and H37Rv. Results are means  standard errors of the means. Statistical significance: , P  0.05. CON,
control.
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healthy subjects responded to PPD and H37Rv, while only 48
to 76% of subjects showed a lymphoproliferative response to
sonicate antigens. Among them, the antigens S7, S10, and S12
induced statistically significant T-cell proliferation (P  0.05)
compared to the control. All sonicate antigen preparations
(except S2 and S8) were potent inducers of IFN-, but only S10
induced statistically significant IFN- levels (P  0.05). The
sonicate antigen preparations also induced IL-12 secretion but
not to a statistically significant extent (data not shown). In our
earlier study, we reported similar types of responses induced by
PPD and heat-killed H37Rv in PPD-positive subjects (7). In
other in vitro studies using PPD and heat-killed mycobacteria
as antigens, the authors reported increases in IFN- levels and
the Th1 type of immune response, thus supporting our obser-
vations (4, 17, 22).
Though PPD and heat-killed H37Rv generated a stronger
immune response, it is highly cross-reactive and nonspecific in
the case of PPD, and many purified antigens of H37Rv, though
specific, are not enough for developing an ideal diagnostic test
or vaccine (14). Hence, there are a need and scope for adding
newer antigens from the most recent and prevalent strains of
M. tuberculosis to induce more specific and stronger immune
responses. In one of the recent reports, Siddiqui et al. have
studied the efficacy of culture filtrate proteins from clinical
isolates of M. tuberculosis; they reported increased T-cell acti-
vation by these antigens compared to that for the standard
laboratory strains and asserted that these culture filtrate pro-
teins are a better source of potential candidates for a tubercu-
losis vaccine (21). Similarly, we planned this study with a view
to identifying the best sonicate antigen from the highly preva-
lent strains from South India that induce protective immunity.
We studied two parameters of protection for these antigens
and found that most antigens induced both T-cell proliferation
and IFN- secretion with a strong positive correlation (r 
0.782) (Fig. 3). Among them S10 and S12 showed compara-
tively higher levels of T-cell activation; however, S10 showed
the best correlation of these two parameters (Fig. 3). Hence,
these antigens look like promising immunogens, which could
be exploited to study their role in mycobacterial immunity and
virulence. The major contribution to IFN- production was
from the activated-sensitized T cells rather than from NK cells,
as the NK cell population in total PBMC is very low.
IL-12 is a crucial cytokine in controlling M. tuberculosis in-
fection. It is secreted by macrophages after stimulation with
mycobacterial antigens and induces IFN- secretion by T cells,
driving the development of the Th1 response (5, 12). All son-
icate antigens induced uniform secretion of IL-12, but no sig-
nificant results were observed. However, the antigens PPD,
H37Rv, S10, and S12, which induced significant levels of
IFN-, induced lower levels of IL-12 than did the control and
other antigens (data not shown). This may be due to IL-12
utilization by appropriate T-cell receptor engagement for stim-
ulation of T-cell proliferation and IFN- secretion (3).
So, in our search for protective antigens, we identified two
South Indian clinical isolates, S10 and S12, which are potent
inducers of T-cell proliferation and also IFN- secretion in
PPD-positive laboratory volunteers. The specific epitopes of
these antigens involved in T-cell activation have to be identi-
fied to obtain a greater protective immune response. These
protective epitopes can then be utilized either for vaccine de-
velopment or for diagnostic tests.
It is known that the occurrence of insertion sequence IS6110
at different sites in the genome may influence phenotypes of
the strains, but at this stage we are not able to directly correlate
the phenotypic differences observed in the protein profiles of
these strains with the immunological parameters studied here.
We are currently looking at the infectivity and apoptosis in-
duced by these strains in relation to immune response. Further
molecular studies are required to establish the influence of
mobile genetic elements in immune response.
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